Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.53−0.01 (-1.40%)
Close on Nov 16, 2026Market cap $14.48MP/E –Yield –
Citius Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Citius Pharmaceuticals's cash was $17.01M at Jun 30, 2026. For fiscal 2025 it was $4.25M, up 30.8% from the year before. Over ten years it grew 181.7% a year on average. The highest annual figure on record is $70.07M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.25M | +30.8% |
| FY2024 | Sep 30, 2024 | $3.25M | -87.7% |
| FY2023 | Sep 30, 2023 | $26.48M | -36.5% |
| FY2022 | Sep 30, 2022 | $41.71M | -40.5% |
| FY2021 | Sep 30, 2021 | $70.07M | +405.6% |
| FY2020 | Sep 30, 2020 | $13.86M | +75.6% |
| FY2019 | Sep 30, 2019 | $7.89M | -14.0% |
| FY2018 | Sep 30, 2018 | $9.18M | +186.6% |
| FY2017 | Sep 30, 2017 | $3.20M | +988.5% |
| FY2016 | Sep 30, 2016 | $294.35K | +217937.8% |
| FY2012 | Sep 30, 2012 | $135 | -36.3% |
| FY2011 | Sep 30, 2011 | $212 | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $17.01M | +179.3% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $4.59M | +17280.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $7.72M | +601.9% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $4.25M | +30.8% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $6.09M | -66.0% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $26.41K | -99.8% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $1.10M | -94.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $3.25M | -87.7% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $17.91M | -46.2% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $12.56M | -66.0% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $20.35M | -51.2% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $26.48M | -44.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $33.28M | -40.3% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $36.89M | -43.6% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $41.71M | -40.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $48.04M | -58.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $55.76M | -46.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $65.42M | +1423.0% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $70.07M | +405.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $115.66M | +1258.0% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $103.70M | +2289.8% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $4.30M | +54.5% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $13.86M | +75.6% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $8.52M | +88.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $4.34M | +35.6% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $2.78M | -60.5% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $7.89M | -14.0% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $4.51M | +63.3% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $3.20M | -36.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $7.04M | -4.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $9.18M | +186.6% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $2.76M | +1289.7% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $5.01M | +8094.8% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $7.37M | +15661.5% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $3.20M | +988.5% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $198.73K | -87.8% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $61.11K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $46.76K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $294.35K | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $1.63M | – |
See a number that looks wrong?